Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

5.17
-0.1400-2.64%
Post-market: 5.350.1800+3.48%19:53 EDT
Volume:1.07M
Turnover:5.57M
Market Cap:714.69M
PE:-1.22
High:5.33
Open:5.31
Low:5.10
Close:5.31
Loading ...

Trump Says Pharma Tariffs Coming Very Soon

Reuters
·
17 Jun

Positive Outlook on Vir Biotechnology’s VIR-5500 Amid Competitive mCRPC Market

TIPRANKS
·
05 Jun

Director Janet Napolitano Reports Disposal of Common Shares in Vir Biotechnology Inc

Reuters
·
03 Jun

Vir Biotechnology Inc. Concluded Annual Stockholders Meeting

Reuters
·
30 May

Vir Biotechnology Price Target Maintained With a $14.00/Share by Needham

Dow Jones
·
22 May

Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Genmab (GMAB) and Vir Biotechnology (VIR)

TIPRANKS
·
22 May

Vir Biotechnology Inc. to Participate in TD Cowen 6th Annual Oncology Innovation Summit

Reuters
·
21 May

Vaccine Stocks Surge with Moderna up 11%

Tiger Newspress
·
20 May

Vir Biotechnology, Inc. : H.c. Wainwright Cuts Target Price to $15 From $110

THOMSON REUTERS
·
20 May

Vir Biotechnology Inc. to Participate in Bank of America Securities 2025 Healthcare Conference

Reuters
·
13 May

Stock Track | Vir Biotechnology Soars 6.10% on Positive Analyst Rating and Trump's Drug Pricing Plan

Stock Track
·
12 May

Vir Biotechnology Is Maintained at Buy by Needham

Dow Jones
·
12 May

Vir Biotechnology (VIR) Receives a Buy from Needham

TIPRANKS
·
12 May

Trump Says He Will Cut Drug Prices by 59%

Reuters
·
12 May

Stock Track | Vir Biotechnology Plummets 5.18% Despite Positive Hepatitis B Treatment Data

Stock Track
·
09 May

Vir Biotechnology Inc - Hbsag Loss Achieved in 17% and 21% of Participants

THOMSON REUTERS
·
09 May

Vir Biotechnology Inc - Reiterates Cash Runway Guidance Into Mid-2027

THOMSON REUTERS
·
09 May

Vir Biotechnology Inc - Tobevibart and Elebsiran Show Consistent Safety Profile

THOMSON REUTERS
·
09 May

Vir Biotechnology Inc - to Streamline March Phase 2 Study

THOMSON REUTERS
·
09 May

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the March Study

THOMSON REUTERS
·
09 May